Project Name: Discovery and Mechanism Research of Immunosuppressants for Triple-negative Breast Cancer Tumor

Project Owner: School of Life Sciences and Biotechnology, SJTU

Project Profile: Triple Negative Breast Cancer (TNBC) is the leading cause of morbidity and mortality among women in the world, and there is still no effective treatment. Aiming at the new targets of TNBC tumor immunotherapy found in the previous cooperation, the Company combines high-throughput screening with drug design, found the targeted tumor immunotherapy drugs for this disease, and carried out preclinical research, providing a new treatment strategy for TNBC disease. Through high-throughput screening of about 40,000 compounds and drug design, a new tumor immunotherapy drug targeting TNBC was found, and the preclinical study was completed. This is a fully autonomous intellectual property project with great medical and social significance.

Contact Person: Zhang Yuyan

Phone Number: 021-24197967

E-mail:zhangyy@sstec.org